179 related articles for article (PubMed ID: 29760800)
1. Risk of immune-related colitis with PD-1/PD-L1 inhibitors vs chemotherapy in solid tumors: systems assessment.
Su Q; Zhang X; Shen X; Hou Y; Sun Z; Gao ZH
J Cancer; 2018; 9(9):1614-1622. PubMed ID: 29760800
[No Abstract] [Full Text] [Related]
2. The Relative Risk of Immune-Related Liver Dysfunction of PD-1/PD-L1 Inhibitors Versus Chemotherapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials.
Deng S; Yang Q; Shu X; Lang J; Lu S
Front Pharmacol; 2019; 10():1063. PubMed ID: 31607917
[No Abstract] [Full Text] [Related]
3. The incidence and relative risk of PD-1/PD-L1 inhibitors-related colitis in non-small cell lung cancer: A meta-analysis of randomized controlled trials.
Lin LL; Lin GF; Luo Q; Chen XQ
Int Immunopharmacol; 2019 Dec; 77():105975. PubMed ID: 31704288
[TBL] [Abstract][Full Text] [Related]
4. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
Nishijima TF; Shachar SS; Nyrop KA; Muss HB
Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
[TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials.
Luo W; Wang Z; Tian P; Li W
J Cancer Res Clin Oncol; 2018 Oct; 144(10):1851-1859. PubMed ID: 30019319
[TBL] [Abstract][Full Text] [Related]
6. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis.
Su Q; Zhu EC; Wu JB; Li T; Hou YL; Wang DY; Gao ZH
Front Immunol; 2019; 10():108. PubMed ID: 30778352
[No Abstract] [Full Text] [Related]
7. Incidence and Risk of Colitis With Programmed Death 1 Versus Programmed Death Ligand 1 Inhibitors for the Treatment of Cancer.
Miyashita H; Mikami T; Satoi S; Cruz C; Galsky MD
J Immunother; 2020; 43(9):291-298. PubMed ID: 32960847
[TBL] [Abstract][Full Text] [Related]
8. Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis.
Guo X; Li W; Hu J; Zhu EC; Su Q
Eur J Clin Pharmacol; 2020 Oct; 76(10):1345-1354. PubMed ID: 32507925
[TBL] [Abstract][Full Text] [Related]
9. The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis.
Ma K; Lu Y; Jiang S; Tang J; Li X; Zhang Y
Front Pharmacol; 2018; 9():1430. PubMed ID: 30618738
[No Abstract] [Full Text] [Related]
10. Immune-Related Pneumonitis Was Decreased by Addition of Chemotherapy with PD-1/L1 Inhibitors: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials (RCTs).
Long YX; Sun Y; Liu RZ; Zhang MY; Zhao J; Wang YQ; Zhou YW; Cheng K; Chen Y; Zhu CR; Liu JY
Curr Oncol; 2022 Jan; 29(1):267-282. PubMed ID: 35049699
[TBL] [Abstract][Full Text] [Related]
11. The Risk Ratio of Immune-Related Colitis, Hepatitis, and Pancreatitis in Patients With Solid Tumors Caused by PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis.
Tian Y; Zhang Z; Yang X; Li D; Zhang L; Li Z; Zhang S; Mao Y; Jin C; Zhao Y
Front Oncol; 2020; 10():261. PubMed ID: 32181158
[No Abstract] [Full Text] [Related]
12. The risk of immune-related endocrine disorders associated with anti-PD-1 inhibitors therapy for solid tumors: A systematic review and meta-analysis.
Su Q; Zhang XC; Wang DY; Zhang HR; Zhu C; Hou YL; Liu JL; Gao ZH
Int Immunopharmacol; 2018 Jun; 59():328-338. PubMed ID: 29679857
[TBL] [Abstract][Full Text] [Related]
13. Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials.
Carretero-González A; Lora D; Ghanem I; Zugazagoitia J; Castellano D; Sepúlveda JM; López-Martin JA; Paz-Ares L; de Velasco G
Oncotarget; 2018 Feb; 9(9):8706-8715. PubMed ID: 29492229
[TBL] [Abstract][Full Text] [Related]
14. Treatment-Related Adverse Events with PD-1 or PD-L1 Inhibitors: A Systematic Review and Meta-Analysis.
Zhang Y; La B; Liang B; Gu Y
Life (Basel); 2021 Nov; 11(11):. PubMed ID: 34833153
[TBL] [Abstract][Full Text] [Related]
15. Network Meta-analysis Comparing Efficacy, Safety and Tolerability of Anti-PD-1/PD-L1 Antibodies in Solid Cancers.
Al-Showbaki L; Nadler MB; Desnoyers A; Almugbel FA; Cescon DW; Amir E
J Cancer; 2021; 12(14):4372-4378. PubMed ID: 34093837
[No Abstract] [Full Text] [Related]
16. The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review.
Chai QQ; Du JY; Zhu J; Wu B
Front Pharmacol; 2019; 10():1260. PubMed ID: 31708783
[No Abstract] [Full Text] [Related]
17. Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis.
Wang X; Bao Z; Zhang X; Li F; Lai T; Cao C; Chen Z; Li W; Shen H; Ying S
Oncotarget; 2017 Aug; 8(35):59901-59914. PubMed ID: 28938692
[TBL] [Abstract][Full Text] [Related]
18. Risk of Gastrointestinal Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Systematic Review and Meta-Analysis.
Yang W; Men P; Xue H; Jiang M; Luo Q
Front Oncol; 2020; 10():197. PubMed ID: 32211312
[No Abstract] [Full Text] [Related]
19. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.
Khunger M; Rakshit S; Pasupuleti V; Hernandez AV; Mazzone P; Stevenson J; Pennell NA; Velcheti V
Chest; 2017 Aug; 152(2):271-281. PubMed ID: 28499515
[TBL] [Abstract][Full Text] [Related]
20. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis.
Wang DY; Ye F; Zhao S; Johnson DB
Oncoimmunology; 2017; 6(10):e1344805. PubMed ID: 29123955
[No Abstract] [Full Text] [Related]
[Next] [New Search]